# Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

> **NCT05491356** · PHASE4 · COMPLETED · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 40 (actual)

## Conditions studied

- Hematoma, Subdural
- Fibrinolytic; Hemorrhage

## Interventions

- **DRUG:** Tissue Plasminogen Activator
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05491356
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-11
- **Primary completion:** 2024-03-30
- **Final completion:** 2024-05-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05491356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05491356, "Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05491356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*